Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Ferme, C;Mounier, N.;Casasnovas, O.;Brice, P.;Gisselbrecht, C.;et.al.
(2006) Blood — Vol. 107, n° 12, p. 4636-4642 (2006)

Files

No attached file found for this publication.

Details

Authors
  • Ferme, C
    Author
  • Mounier, N.
    Author
  • Casasnovas, O.
    Author
  • Brice, P.
    Author
  • Gisselbrecht, C.
    Author
Show more
Abstract
From 1989 to 1996, 533 eligible patients with stage IIIB/IV Hodgkin lymphoma (HL) were randomly assigned to receive 6 cycles of hybrid MOPP/ABV (mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine; n = 266) or ABVPP (doxorubicin, bleomycin, vinblastine, procarbazine, prednisone; n = 267). Patients in complete remission (CR) or partial response of at least 75% after 6 cycles received 2 cycles of consolidation chemotherapy (CT) (n = 208) or sub total nodal irradiation (RT) (n = 210). A better survival probability was observed after ABVPP alone: the 10-year overall survival (OS) estimates were 90% for ABVPPx8, 78% for MOPP/ABVx8, 82% for MOPP/ABV with FIT, and 77% for ABVPPx6 with RT (P = .03); and the 10-year disease-free survival (DFS) estimates were 70%, 76%, 79%, and 76%, respectively (P = .09). The 10-year DFS estimates for patients treated with consolidation CT or RT were 73% and 78% (P = .07), and OS estimates were 84% and 79%, respectively (P = .29). These results showed that RT was not superior to consolidation CT after a doxorubicin-induced CR in patients with advanced HL. An analysis of competing risks identified age more than 45 years as a significant risk factor for death, relapse, and second cancers. Prospective evaluation of late adverse events may improve the management of patients with HL.
Affiliations

Citations

Ferme, C., Mounier, N., Casasnovas, O., Brice, P., Divine, M., Sonet, A., Bouafia, F., Bastard-Stamatoullas, A., Bordessoule, D., Voillat, L., Reman, O., Blanc, M., & Gisselbrecht, C. (2006). Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood, 107(12), 4636-4642. https://doi.org/10.1182/blood-2005-11-4429 (Original work published 2006)